mw03, you're right mate. IGF-1 is being tested because it is already approved by the FDA for growth related conditions. It is definitely a competitor.
There are a couple of reasons why nnz-2566 walks all over IGF-1 though.
1. nnz-2566 is orally available while IGF-1 requires injections.
2. IGF-1 cannot be used with older patients in all diseases as it will promote excessive growth, while nnz-2566 does not have that issue.
- Forums
- ASX - By Stock
- NEU
- Wider autism efficacy potential for nnz-2566
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.31%
!
$14.65

Wider autism efficacy potential for nnz-2566, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.65 |
Change
0.470(3.31%) |
Mkt cap ! $1.820B |
Open | High | Low | Value | Volume |
$14.36 | $14.75 | $14.36 | $9.182M | 629.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 830 | $15.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.88 | 3476 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 1344 | 15.380 |
7 | 2508 | 15.360 |
4 | 1899 | 15.120 |
7 | 6220 | 15.080 |
3 | 2701 | 14.980 |
Price($) | Vol. | No. |
---|---|---|
13.880 | 2560 | 4 |
13.920 | 11517 | 2 |
13.960 | 106 | 1 |
14.220 | 346 | 2 |
14.230 | 352 | 1 |
Last trade - 15.59pm 10/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |